Department of Oncology, Charing Cross Hospital, Fulham Palace Road, London, United Kingdom.
Hong Kong Med J. 2013 Dec;19(6):549-52. doi: 10.12809/hkmj133798.
Three patients with pure red cell aplasia, with or without co-existing large granular lymphocytic leukaemia, who remained transfusion-dependent despite treatment with established first-line therapy, were treated with low-dose subcutaneous alemtuzumab 15 mg twice to thrice per week, for 3 to 4 weeks. The mean response time was 17 days compared with a response time of at least 61 days on standard first-line therapy. There were no serious side-effects and the mean duration of remission was 13 months. Low-dose subcutaneous alemtuzumab is a safe and effective treatment for pure red cell aplasia and further trials should be conducted to compare the long-term effectiveness of this treatment with conventional therapy.
三位纯红细胞再生障碍性贫血患者，无论是否伴有大颗粒淋巴细胞白血病共存，在接受既定一线治疗后仍依赖输血，接受每周两次至三次、每次 15 毫克的低剂量皮下阿伦单抗治疗，持续 3 至 4 周。平均反应时间为 17 天，而标准一线治疗的反应时间至少为 61 天。没有严重的副作用，平均缓解持续时间为 13 个月。低剂量皮下阿伦单抗是治疗纯红细胞再生障碍性贫血的一种安全有效的方法，应进一步进行临床试验，比较这种治疗方法与常规治疗的长期疗效。
